a). A portion of a scanned cDNA microarray showing the differential expression of granzyme H. The cDNA fragment spotted on position F12 corresponds to granzyme H (indicated by arrow). (I). Hybridization profile for LGL leukemia cells. (II). Hybridization profile for control. Balanced differential expression, 6.3. b). Shows the differential expression of Granzyme B in oligonucleotide array. Calculated fold change is 20.5 (I). Hybridization pattern for the granzyme B probe set (with RNA isolated from normal PBMC), PM = Perfect match, MM = Mismatch. (II). Hybridization pattern for the granzyme B probe set (with RNA isolated from leukemic LGL), PM = Perfect match, MM = Mismatch c). Northern blot showing expression of granzyme B/H. The probe used was the same as the probes spotted on the microarray. Lane LGL = total RNA samples isolated from LGL leukemia patient Lane N = total RNA isolated from normal healthy control. NA = Total RNA isolated from PBMC of a normal healthy individual activated with IL2 and PHA. d). RNase protection assay for granzyme B. Probe set hAPO-4 obtained from PharMingen contains a specific probe for granzyme B. Note: Leukemic LGL cells over-expressed granzyme B (Lane LGL), whereas very low levels of granzyme B were observed in PBMC from normal healthy control (Lane N). Normal activated PBMC showed strong expression of granzyme B (Lane NA). e). RNase protection assay for granzyme H. Probe set hAPO-4 obtained from PharMingen contains a specific probe for granzyme H. Leukemic LGL cells showed over-expression (Lane LGL). PBMC obtained from a normal healthy individual (Lane N) and activated PBMC showed trace expression.